The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ledbetter, J. A.
Right arrow Articles by June, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ledbetter, J. A.
Right arrow Articles by June, C. H.

The Journal of Immunology, Vol 137, Issue 10 3299-3305, Copyright © 1986 by American Association of Immunologists


ARTICLES

Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP- mediated suppression

JA Ledbetter, M Parsons, PJ Martin, JA Hansen, PS Rabinovitch and CH June

T cells can be activated to proliferate by antibodies to the T cell antigen receptor or the molecularly associated CD3 complex if monocytes are present. We have shown previously that monoclonal antibodies to the human T cell differentiation antigens CD5 (Tp67) and Tp44 each augment and prolong proliferative responses of anti-CD3-activated T cells, even in the absence of monocytes. Here we show that the functional and biochemical mechanisms of CD5 and Tp44 signal transmission are distinct. T cell proliferation is suppressed by agents that increase the concentration of intracellular cAMP. We found that antibody binding to the Tp44 surface molecule overcomes this suppression, whereas antibody binding to CD5 does not, indicating that ligand-Tp44 interaction changes T cell sensitivity to cAMP-mediated growth inhibition. The ability of anti-CD3, anti-Tp44, and anti-CD5 monoclonal antibodies to directly alter cyclic nucleotide levels in the Jurkat T cell line was examined. Anti-CD3 alone caused a rapid four- to sixfold increase in cAMP levels, but did not affect cGMP levels. However, anti- Tp44 and anti-CD5 each caused a rapid three- to fourfold increase in cGMP levels without affecting cAMP levels. In other experiments, cytoplasmic free calcium levels were measured in resting T cells after CD5 or Tp44 stimulation by using the dye indo-1 and flow cytometry. This sensitive method showed that anti-CD5 alone caused an increase in cytoplasmic calcium free levels within 3 min of antibody addition, whereas anti-Tp44 had no effect. Finally, anti-Tp44 and IL 1 each augmented proliferation of phorbol ester-stimulated lymphocytes, whereas anti-CD5 did not. The effects of IL 1 and Tp44 could be further distinguished in that the effect of anti-Tp44 was resistant to inhibition by dBcAMP whereas IL 1 was not. These data suggest that the receptor function of both Tp44 and CD5 involves changes in cyclic nucleotides levels, and that the mechanism by which anti-Tp44 and anti- CD5 antibodies affect T cell proliferative responses may be related to their selective effects on cGMP levels and cytoplasmic calcium concentrations.


This article has been cited by other articles:


Home page
J. Immunol.Home page
D. Peter, S. L. C. Jin, M. Conti, A. Hatzelmann, and C. Zitt
Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D
J. Immunol., April 15, 2007; 178(8): 4820 - 4831.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Vendetti, M. Patrizio, A. Riccomi, and M. T. De Magistris
Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP
J. Leukoc. Biol., October 1, 2006; 80(4): 880 - 888.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. J. O'Connell, X. Wang, M. Leon-Ponte, C. Griffiths, S. C. Pingle, and G. P. Ahern
A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells
Blood, February 1, 2006; 107(3): 1010 - 1017.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Abrahamsen, G. Baillie, J. Ngai, T. Vang, K. Nika, A. Ruppelt, T. Mustelin, M. Zaccolo, M. Houslay, and K. Tasken
TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling
J. Immunol., October 15, 2004; 173(8): 4847 - 4858.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K.-Z. Dai, F.-E. Johansen, K. M. Kolltveit, H.-C. Aasheim, Z. Dembic, F. Vartdal, and A. Spurkland
Transcriptional Activation of the SH2D2A Gene Is Dependent on a Cyclic Adenosine 5'-Monophosphate-Responsive Element in the Proximal SH2D2A Promoter
J. Immunol., May 15, 2004; 172(10): 6144 - 6151.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Arp, M. G. Kirchhof, M. L. Baroja, S. H. Nazarian, T. A. Chau, C. A. Strathdee, E. H. Ball, and J. Madrenas
Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation
Mol. Cell. Biol., November 15, 2003; 23(22): 8042 - 8057.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. M. Harlan and A. D. Kirk
The Future of Organ and Tissue Transplantation: Can T-Cell Costimulatory Pathway Modifiers Revolutionize the Prevention of Graft Rejection?
JAMA, September 15, 1999; 282(11): 1076 - 1082.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. F. Krummel, W. R. Heath, and J. Allison
Differential Coupling of Second Signals for Cytotoxicity and Proliferation in CD8+ T Cell Effectors: Amplification of the Lytic Potential by B7
J. Immunol., September 15, 1999; 163(6): 2999 - 3006.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. L. Baroja, L. B. Cieslinski, T. J. Torphy, R. L. Wange, and J. Madrenas
Specific CD3{varepsilon} Association of a Phosphodiesterase 4B Isoform Determines Its Selective Tyrosine Phosphorylation After CD3 Ligation
J. Immunol., February 15, 1999; 162(4): 2016 - 2023.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Aukrust, E. M. Aandahl, B. S. Skalhegg, I. Nordoy, V. Hansson, K. Tasken, S. S. Froland, and F. Muller
Increased Activation of Protein Kinase A Type I Contributes to the T Cell Deficiency in Common Variable Immunodeficiency
J. Immunol., January 15, 1999; 162(2): 1178 - 1185.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
E. M. Aandahl, P. Aukrust, B. S. Skålhegg, F. Müller, S. S. Frøland, V. Hansson, and K. Taskén
Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients
FASEB J, July 1, 1998; 12(10): 855 - 862.
[Abstract] [Full Text]


Home page
J. Exp. Med.Home page
X. C. Liao, S. Fournier, N. Killeen, A. Weiss, J. P. Allison, and D. R. Littman
Itk Negatively Regulates Induction of  T Cell Proliferation by CD28 Costimulation
J. Exp. Med., July 21, 1997; 186(2): 221 - 228.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
B. Skalhegg, K Tasken, V Hansson, H. Huitfeldt, T Jahnsen, and T Lea
Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex
Science, January 7, 1994; 263(5143): 84 - 87.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.